Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma (1998)
    Springer
    Annals of oncology 9 (1998), S. 37-43 
    Details
    ISSN: 1569-8041
    Keywords: carboplatin ; chemotherapy ; ovarian carcinoma ; paclitaxel
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: Platinum compounds are the most active drugs in ovarian cancer treatment; cisplatin and carboplatin demonstrated similar efficacies but different toxicity profiles. Paclitaxel combined with cisplatin as first-line treatment improved overall survival when compared to a cisplatin-cyclophosphamide combination, but generated higher rates of neutropenia, febrile neutropenia and neurotoxicity. The paclitaxel-carboplatin combination may be better tolerated than cisplatin–paclitaxel. Design: The objective of the present study was to assess the efficacy and safety of the combination of paclitaxel and carboplatin in previously treated advanced ovarian cancer patients. Patients and methods: During or after platinum-based chemotherapy, 73 patients with progressive advanced epithelial ovarian carcinoma were enrolled to receive every four weeks a three-hour infusion of paclitaxel 175 mg/m2 followed by a 30-minute carboplatin infusion. The carboplatin dose was calculated to obtain the recommended area concentration-versus-time under the curve of 5 mg·ml-1·min. Results: Toxicity and response could be evaluated for 72 and 62 patients, respectively. Eleven complete and 15 partial responses gave an overall response rate of 42% (95% CI: 30%–54%). Response rates for platinum-refractory patients and those with early (≥3 and 〈12 months) and late (〉12 months) relapses were 24%, 33% and 70%, respectively. The respective median response duration, the median progression-free survival and median overall survival were 8, 6 and 14 months. Myelosuppression was the most frequent and severe toxicity. Grade 3 and 4 neutropenia occurred, respectively in 30% and 23% of the cycles; 6% of the cycles benefited from medullary growth factors. Only one episode of febrile neutropenia was observed. Grade 3 and 4 thrombocytopenia occurred, respectively during 3% and 1% of the cycles. Alopecia was frequent. Transient peripheral neuropathy developed in 47% of patients but was severe in only one patient. One early death was attributed to progressive disease and possibly to therapy. Conclusion: This combined paclitaxel–carboplatin therapy is effective and can be safely administered to ovarian cancer patients who relapse after one or two regimens of platinum-based chemotherapy.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008211909585
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma (2000)
    Springer
    Annals of oncology 11 (2000), S. 1471-1476 
    Details
    ISSN: 1569-8041
    Keywords: 5-FU continuous infusion ; metastatic breast carcinoma ; multidrug resistance ; verapamil
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background:Verapamil (VER), a potent calcium channel blocker, hasbeen found to overcome P-gp-mediated multi-drug resistance (MDR) and toincrease sensitivity to cytotoxic anticancer drugs in refractory myeloma andnon-Hodgkin lymphoma. The value of VER for treating solid tumors is still amatter for debate. Patients and methods:We performed a prospective study in 99patients with anthracycline-resistant metastatic breast carcinoma (MBC), toassess the clinical effect of oral VER given in association with chemotherapy.Instead of retreating patients with anthracycline, we used a partiallynoncross-resistant regimen (VF), combining vindesine (VDS) and 5-fluorouracilgiven as a continuous infusion (5-FU CI). Patients were randomly assigned totwo cohorts. One cohort (47 patients) was treated in 28-day cycles, eachinvolving the administration of VDS (3 mg/m2 i.v. bolus on days 1and 10) and 5-FU CI, (400 mg/m2/day i.v. from day 1 to day 10). Theother cohort (52 patients) received the same VDS and 5-FU treatment and anadditional oral VER treatment (240 mg/day divided in 2 doses), from day 1 today 28 of each cycle. Patients were treated until progression. Results:The treatment was well tolerated and no side effects thatcould be attributed to VER were detected. Patients treated with VER had longeroverall survival (OS) (median OS: 323 vs. 209 days, P = 0.036) anda higher response rate (27% vs. 11%, P = 0.04) thanthose not given VER. Progression-free survival (PFS) was also longer but thedifference was not statistically significant (median PFS: 4.6 and 2.7 monthsfor the VER and non-VER groups respectively, P = 0.6). Conclusions:This clinical trial demonstrates that achemosensitizer, such as VER, can increase the survival of MBC patients withacquired anthracycline resistance.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1026556119020
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen (1992)
    Springer
    Breast cancer research and treatment 24 (1992), S. 139-145 
    Details
    ISSN: 1573-7217
    Keywords: aminoglutethimide ; breast cancer ; endocrine therapy ; medroxyprogesterone acetate ; tamoxifen
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary In order to evaluate the efficacy of two different sequences of second and third line hormonotherapy in advanced post-menopausal breast cancer, 257 women aged 36–91 years (mean age: 63.6 years) who had become resistant to tamoxifen (TAM), entered into a multicenter randomized trial comparing two different regimens: 1) Aminoglutethimide (Ag) 500 mg/day with hydrocortisone supplementation from 30 to 60 mg/day; and 2) oral medroxyprogesterone acetate (MPA) 500 mg twice a day. 250 patients were evaluated following second line hormone therapy and, after cross-over, 128 following third line hormonotherapy. No significant difference was observed, during either second or third line therapies, for toxicity, survival, or response rate; however, in both second and third line therapies the median time to progression was significantly longer with Ag therapy.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01961246
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...